Frequent Germ-Line Mutations of the MEN1, CASR, and HRPT2/CDC73 Genes in Young Patients with Clinically Non-familial Primary Hyperparathyroidism

Hormones and Cancer

Volumn 3, Issue 1-2, 2012, Pages 44-51

  Starker, Lee F ^a,c   Åkerström, Tobias ^a   Long, William D ^a   Delgado Verdugo, Alberto ^a,c   Donovan, Patricia ^a   Udelsman, Robert ^a   Lifton, Richard P ^a   Carling, Tobias ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Familial syndromes; Hyperparathyroidism; MEN1; Parathyroid

Indexed keywords

CALCIUM; PARATHYROID HORMONE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CASR GENE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GERM LINE; HRPT2 CDC73 GENE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MEN1 GENE; NEPHROLITHIASIS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; POLYPHENISM; POSTOPERATIVE PERIOD; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; FEMALE; GERM-LINE MUTATION; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RECEPTORS, CALCIUM-SENSING; TUMOR SUPPRESSOR PROTEINS;

EID: 84856669927     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-011-0100-8     Document Type: Article

References (32)

1. Heppner C, Kester MB, Agarwal SK, Debelenko LV, Emmert-Buck MR, Guru SC, Manickam P, Olufemi S-E, Skarulis MC, Doppman JL, Alexander RH, Kim YS, Saggar SK, Lubensky IA, Zhuang Z, Liotta LA, Chandrasekharappa SC, Collins FS, Speigel AM, Burns AL, Mark SJ (1997) Somatic mutations of the MEN1 gene in parathyroid tumours. Nature Genet 16: 375-378.
2. Carpten JDRC, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, Hoog A, Heath H, James-Newton LA, Robinson B, Zarbo RJ, Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo LO, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, Teh BT, Larsson C, Hobbs MR (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32: 676-680.
3. Pollak MR, Brown EM, Chou YH, Hebert SC, Marx SJ, Steinmann B, Levi T, Seidman CE, Seidman JG (1993) Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75: 1297-1303.
4. Stalberg P, Carling T (2009) Familial parathyroid tumors: diagnosis and management. World J Surg 33: 2234-2243.
5. Marx SJSW, Agarwal SK, Burns AL, Weinstein LS, Cochran C, Skarulis MC, Spiegel AM, Libutti SK, Alexander HR Jr, Chen CC, Chang R, Chandrasekharappa SC, Collins FS (2002) Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res Suppl 2: N37-N43.
6. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr (2005) Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 353: 1105-1113.
7. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86: 5658-5671.
8. Skogseid B, Rastad J, Oberg K (1994) Multiple endocrine neoplasia type 1. Clinical features and screening. Endocrinol Metab Clin North Am 23: 1-18.
9. Wassif WS, Moniz CF, Friedman E, Wong S, Weber G, Nordenskjöld M, Peters TJ, Larsson C (1993) Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab 77: 1485-1489.
10. Simonds WF, James-Newton LA, Agarwal SK, Yang B, Skarulis MC, Hendy GN, Marx SJ (2002) Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore) 81: 1-26.
11. Thorgeirsson U, Costa J, Marx SJ (1981) The parathyroid glands in familial hypocalciuric hypercalcemia. Hum Pathol 12: 229-237.
12. Marx SJ, Stock JL, Attie MF, Downs R Jr, Gardner DG, Brown EM, Spiegel AM, Doppman JL, Brennan MF (1980) Familial hypocalciuric hypercalcemia: recognition among patients referred after unsuccessful parathyroid exploration. Ann Intern Med 92: 351-356.
13. Carling T, Szabo E, Bai M, Ridefelt P, Westin G, Gustavsson P, Trivedi S, Hellman P, Brown EM, Dahl N, Rastad J (2000) Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab 85: 2042-2047.
14. Guarnieri V, Canaff L, Yun FH, Scillitani A, Battista C, Muscarella LA, Wong BY, Notarangelo A, D'Agruma L, Sacco M, Cole DE, Hendy GN (2010) Calcium-sensing receptor (CASR) mutations in hypercalcemic states: studies from a single endocrine clinic over three years. J Clin Endocrinol Metab 95: 1819-1829.
15. Carling T, Rastad J, Szabo E, Westin G, Åkerström G (2000) Reduced vitamin D receptor mRNA levels in parathyroid glands of primary and secondary hyperparathyroidism. J Clin Endocrinol 85: 2000-2003.
16. Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Rejnmark L, Brixen K, Mosekilde L (2008) Plasma 25-hydroxyvitamin D, 1, 25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism. Eur J Endocrinol 159: 719-727.
17. Sharretts JM, Simonds WF (2010) Clinical and molecular genetics of parathyroid neoplasms. Best Pract Res Clin Endocrinol Metabol 24: 491-502.
18. Oucharek JJ, O'Neill CJ, Suliburk JW, Sywak MS, Delbridge LW, Sidhu SB (2011) Durability of focused minimally invasive parathyroidectomy in young patients with sporadic primary hyperparathyroidism. Ann Surg Oncol 18: 1290-1292.
19. Skandarajah A, Barlier A, Morlet-Barlat N, Sebag F, Enjalbert A, Conte-Devolx B, Henry JF (2010) Should routine analysis of the MEN1 gene be performed in all patients with primary hyperparathyroidism under 40 years of age? World J Surg 34: 1294-1298.
20. Carling T, Udelsman R (2008) Focused approach to parathyroidectomy. World J Surg 32: 1512-1517.
21. Carling T, Correa P, Hessman O, Hedberg J, Skogseid B, Lindberg D, Rastad J, Westin G, Akerstrom G (1998) Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. J Clin Endocrinol Metab 83: 2960-2963.
22. Shattuck TM, Costa J, Bernstein M, Jensen RT, Chung DC, Arnold A (2002) Mutational analysis of Smad3, a candidate tumor suppressor implicated in TGF-beta and menin pathways, in parathyroid adenomas and enteropancreatic endocrine tumors. J Clin Endocrinol Metab 87: 3911-3914.
23. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249.
24. Corbo V, Dalai I, Scardoni M, Barbi S, Beghelli S, Bersani S, Albarello L, Doglioni C, Schott C, Capelli P, Chilosi M, Boninsegna L, Becker KF, Falconi M, Scarpa A (2010) MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Canc 17: 771-783.
25. Kihara M, Miyauchi A, Ito Y, Yoshida H, Miya A, Kobayashi K, Takamura Y, Fukushima M, Inoue H, Higashiyama T, Tomoda C (2009) MEN1 gene analysis in patients with primary hyperparathyroidism: 10-year experience of a single institution for thyroid and parathyroid care in Japan. Endocr J 56: 649-656.
26. Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, Rao DS, Rubin MR, Goltzman D, Silverberg SJ, Marx SJ, Peacock M, Mosekilde L, Bouillon R, Lewiecki EM (2009) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94: 340-350.
27. Bilezikian JP, Khan AA, Potts JT Jr (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94: 335-339.
28. Howell VM, Zori RT, Stalker HJ, Williams C, Jesse N, Nelson AE, Robinson BG, Marsh DJ (2004) A molecular diagnosis of hyperparathyroidism-jaw tumor syndrome in an adolescent with recurrent kidney stones. J Pediatr 145: 567.
29. Szabo E, Carling T, Hessman O, Rastad J (2002) Loss of heterozygosity in parathyroid glands of familial hypercalcemia with hypercalciuria and point mutation in calcium receptor. J Clin Endocrinol Metab 87: 3961-3965.
30. Cardinal JW, Bergman L, Hayward N, Sweet A, Warner J, Marks L, Learoyd D, Dwight T, Robinson B, Epstein M, Smith M, Teh BT, Cameron DP, Prins JB (2005) A report of a national mutation testing service for the MEN1 gene: clinical presentations and implications for mutation testing. J Med Genet 42: 69-74.
31. Lundgren E, Rastad J, Thrufjell E, Akerström G, Ljunghall S (1997) Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 121: 287-294.
32. Agarwal SK, Mateo CM, Marx SJ (2009) Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 94: 1826-1834.